- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MAIA BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| Mi | MAIA Biotechnology, Inc.: MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal | 176 | GlobeNewswire (Europe) | THIO-104 advances toward key 2027 interim survival analysis CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| Di | MAIA Biotechnology, Inc.: MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer | 235 | GlobeNewswire (Europe) | Strong pace of patient enrollment supports continued advancement toward regulatory milestones Most recent assessment of novel telomere targeting agent sequenced with a checkpoint inhibitor showed... ► Artikel lesen | |
| 16.09. | MAIA Biotechnology, Inc.: MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial | 407 | GlobeNewswire (Europe) | Milestone follows FDA clearance of MAIA's amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies U.S. expansion is funded by a $2.3 million... ► Artikel lesen | |
| 15.09. | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO | 1 | GlobeNewswire (USA) | ||
| 10.09. | MAIA Biotechnology, Inc.: MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026 | 2 | GlobeNewswire (USA) | ||
| 10.08. | MAIA Biotechnology, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.07. | MAIA Biotechnology, Inc.: MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial | 402 | GlobeNewswire (Europe) | 90.5% interim disease control rate (DCR) observed with combination therapy Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-treated... ► Artikel lesen | |
| 25.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer | 336 | GlobeNewswire (Europe) | Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June 25, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage... ► Artikel lesen | |
| 18.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University | 323 | GlobeNewswire (Europe) | Georgia's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recognized at the forefront of cancer innovation and discovery nationwide CHICAGO, June 18, 2026 (GLOBE... ► Artikel lesen | |
| 10.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial | 369 | GlobeNewswire (Europe) | Additional data from MAIA's THIO-101 expansion may further support an accelerated approval filing with the FDA Potential breakthrough therapy holds substantial commercial opportunity in a projected... ► Artikel lesen | |
| 04.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial | 320 | GlobeNewswire (Europe) | MAIA's novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cancer CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE... ► Artikel lesen | |
| 03.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion | 342 | GlobeNewswire (Europe) | Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDA FDA-cleared IND updates detail latest efficacy data and enriched manufacturing... ► Artikel lesen | |
| 02.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces Open Market Purchases by CEO and Director | 3 | GlobeNewswire (USA) | ||
| 22.05. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.05. | MAIA Biotechnology, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 16.04. | MAIA Biotechnology opens first U.S. site for lung cancer trial | 1 | Investing.com | ||
| 16.04. | MAIA Biotechnology, Inc.: MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer | 332 | GlobeNewswire (Europe) | Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above standard of care benchmarks 50,000 advanced NSCLC... ► Artikel lesen | |
| 16.04. | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.04. | MAIA Biotechnology expects $33M capital raise to fund Phase 3 trial of anticancer therapy | 1 | Seeking Alpha |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 131,68 | -0,98 % | Gilead Sciences und Assembly Bio: Kommt am 13. Oktober der Herpes-Paukenschlag? | Bei Gilead Sciences verdichten sich derzeit die Hinweise darauf, dass der Pharmakonzern in den kommenden Jahren das Therapiefeld der Virologie massiv ausbauen und damit die langfristige Abhängigkeit... ► Artikel lesen | |
| ABBVIE | 232,20 | -0,34 % | AbbVie reicht EU-Beihilfebeschwerde gegen Regelungen des GKV-Beitragssatzstabilisierungsgesetzes ein und warnt vor ungleichem Zugang zu innovativen Arzneimitteln | Wiesbaden (ots) - - AbbVie Deutschland hat eine Beschwerde eingereicht und die Europäische Kommission gebeten zu prüfen, ob die Regelungen des GKV-Beitragssatzstabilisierungsgesetzes zu wirkstoffübergreifenden... ► Artikel lesen | |
| ABBOTT LABORATORIES | 89,10 | -2,02 % | Abbott Laboratories (ABT) is Facing Segment Competition and Sluggish Nutrition Recovery | ||
| SCHOTT PHARMA | 24,600 | +3,36 % | Schott Pharma: Was JPMorgans Kaufvotum jetzt auslöst | ||
| EYEPOINT | 3,300 | +0,61 % | XFRA PV3B: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 76,16 | -0,16 % | Edwards Lifesciences taps GE HealthCare vet to head new digital engineering group | ||
| ASSEMBLY BIOSCIENCES | 21,600 | +2,61 % | Assembly Biosciences: Was am 13. Oktober entscheidet | ||
| PENTIXAPHARM | 1,890 | +0,80 % | EQS-DD: Pentixapharm Holding AG: Eckert Wagniskapital und Frühphasenfinanzierung GmbH, Erwerb von Aktien durch Ausübung von Bezugsrechten | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
17.08.2026 / 09:19... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 55,00 | +8,57 % | Nektar Therapeutics drops as jury deliberates in Eli Lilly patent dispute over Rezpeg | ||
| FILANA THERAPEUTICS | 0,745 | -5,10 % | XFRA PX91: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILFILANA THERAPEU.... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 169,60 | -0,24 % | Axsome Therapeutics, Inc.: Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer's Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer's Day | The Shared Goals: Navigating Alzheimer's Agitation survey finds that Alzheimer's disease agitation is often only recognized after daily life is significantly disrupted Ninety-seven percent of care... ► Artikel lesen | |
| MEDPACE | 552,00 | +1,81 % | Insider Transaction: August J Troendle Sells $44.43M Worth Of Medpace Holdings Shares | ||
| ZEALAND PHARMA | 36,890 | +0,30 % | Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity | Press release - No. 17 / 2026 Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity The Phase 3 initiation marks a... ► Artikel lesen | |
| UNITED THERAPEUTICS | 416,80 | -3,02 % | United Therapeutics, Sagimet drop after Goldman Sachs Sell ratings | ||
| UCB | 213,10 | -0,51 % | UCB stellt bei J.P. Morgan Wachstumsstrategie vor: BIMZELX als treibende Kraft |
MAIA BIOTECHNOLOGY INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 1,260 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAIA BIOTECHNOLOGY INC finden Sie auf Wallstreet Online.